A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

American Health Network Indiana, Indianapolis, Indiana, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Willing and able to provide written informed consent
At least 18 years of age
Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
Initiating panobinostat within 60 days of enrollment
ECOG performance status 0-1
Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
Willing and able to complete the PRO questionnaire

Exclusion criteria

Diagnosed with any B-cell malignancy other than myeloma
Estimated life expectancy <6 months
Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

Treatment and study plan

Farydak

Drug

non-interventional study

Primary outcomes

Response to treatment

Time frame: 24 months

Looking for patient reproted response to treatment with panobinostat

Sponsors and collaborators

Lead sponsor

pharmaand GmbH

Industry

Registry information

Official study title

A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)

Acronym: RECOMM

Important dates

Study start: 2019
Primary completion: 2022
Study completion: 2022
First posted: Nov 4, 2019
Registry last updated: Jun 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed